Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States

Cancer

Volumn 120, Issue 15, 2014, Pages 2308-2315

  Guy, Gery P ^a   Richardson, Lisa C ^a,c   Pignone, Michael P ^b   Plescia, Marcus ^a,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^d Mecklenburg County Health Department   (United States)

Author keywords

colorectal cancer; early detection; health economics; public health; screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COST BENEFIT ANALYSIS; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; IMMUNOCHEMISTRY; IMMUNOLOGY TEST KIT; INVESTMENT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCREENING TEST; UNITED STATES; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; MALE; MIDDLE AGED; OCCULT BLOOD;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED; OCCULT BLOOD; UNITED STATES;

EID: 84904718649     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28724     Document Type: Article

References (41)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. www.cdc.gov/uscs. Accessed February 25, 2014.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML,. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
3. Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC,. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011; 65 (5 suppl 1): S133-S143.
4. US Preventive Services Task Force. Screening for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2008. uspreventiveservicestaskforce.org/uspstf/uspscolo.htm. Accessed March 2, 2013.
5. Lansdorp-Vogelaar I, Knudsen AB, Brenner H,. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011; 33: 88-100.
6. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JDF, Kuipers EJ,. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009; 101: 1412-1422.
7. Dobson A, Sen N, DaVanzo J,. Methodology for Estimating the Potential Cost Savings to Medicare from Increased Colorectal Cancer Screening of the Pre-Medicare Population. nccrt.org/about/policy-action/savings-to-medicare/. Accessed March 2, 2013.
8. Stanley SL, King JB, Thomas CC, Richardson LC,. Factors associated with never being screened for colorectal cancer. J Community Health. 2013; 38: 31-39.
9. Centers for Disease Control and Prevention (CDC). Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61: 41-45.
10. US Department of Health and Human Services. Healthy People 2020. healthypeople.gov/2020/topicsobjectives2020/default.aspx. Accessed March 12, 2013.
11. Koh HK, Sebelius KG,. Promoting prevention through the Affordable Care Act. N Engl J Med. 2010; 363: 1296-1299.
12. Sabatino SA, Lawrence B, Elder R, et al. Community Preventive Services Task Force. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: 9 updated systematic reviews for the guide to community preventive services. Am J Prev Med. 2012; 43: 97-118.
13. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C,. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011; 33: 101-110.
14. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med. 2013; 173: 1725-1732.
15. Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS,. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008; 122: 1357-1367.
16. US Census Bureau. Single Years of Age and Sex: 2010. factfinder2. census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid= DEC-10-SF1-QTP2&prodType=table. Accessed March 12, 2013.
17. Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JDF, van Ballegooijen M,. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer. 2011; 117: 4166-4174.
18. Cole S, Smith A, Wilson C, Turnbull D, Esterman A, Young GP,. An advance notification letter increases participation in colorectal cancer screening. J Med Screen. 2007; 14: 73-75.
19. Lee JK, Reis V, Liu S, et al. Improving fecal occult blood testing compliance using a mailed educational reminder. J Gen Intern Med. 2009; 24: 1192-1197.
20. Van Rossum L, Van Rijn AF, Laheij R, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135: 82-90.
21. Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J,. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev. 2003; 60: 294-331.
22. Myers RE, Turner B, Weinberg D, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004; 38: 375-381.
23. Turner B, Myers RE, Hyslop T, et al. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003; 18: 357-363.
24. Centers for Medicare and Medicaid Services. Physician Fee Schedule Search HCPCS Code 11400-11646. cms.gov/apps/physician-fee-schedule/search/search- results.aspx?Y=0&T=0&HT=2&CT=0&H1-11400&H2=11646&M=5. Accessed April 10, 2013.
25. Zauber AG,. Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am. 2010; 20: 751-770.
26. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med. 2006; 145: 880-886.
27. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006; 355: 1863-1872.
28. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000; 343: 162-168.
29. Subramanian S, Tangka FK, Hoover S, DeGroff A, Royalty J, Seeff LC,. Clinical and programmatic costs of implementing colorectal cancer screening: evaluation of five programs. Eval Program Plann. 2011; 34: 147-153.
30. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011; 128: 2415-2424.
31. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR,; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143: 844-857.
32. Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJ,. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust. 2011; 194: 180-185.
33. Pox C, Schmiegel W, Classen M,. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007; 39: 168-173.
34. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ,. Colorectal cancer screening: health impact and cost effectiveness. Am J Prev Med. 2006; 31: 80-89.
35. Subramanian S, Tangka FK, Hoover S, et al. International Comparison of Economic Assessments of Colorectal Cancer Screening Programs: Preliminary Results. Presented at the 2012 CDC National Cancer Conference; August 21-23, 2012; Washington, DC.
36. Levin TR,. Optimizing colorectal cancer screening by getting FIT right. Gastroenterology. 2011; 141: 1551-1555.
37. Grubbs SS, Polite BN, Carney J Jr, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013; 31: 1928-1930.
38. Cole SR, Tucker GR, Osborne JM, et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013; 198: 327-330.
39. Hoerger TJ, Ekwueme DU, Miller JW, et al. Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality. Am J Prev Med. 2011; 40: 397-404.
40. Ekwueme DU, Gardner JG, Subramanian S, Tangka FK, Bapat B, Richardson LC,. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004. Cancer. 2008; 112: 626-635.
41. Jean-Jacques M, Kaleba EO, Gatta JL, Gracia G, Ryan ER, Choucair BN,. Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized control trial. Ann Fam Med. 2012; 10: 412-417.